clinical-stage

Nasus Pharma CEO presents clinical pipeline at three major healthcare conferences in February-March, showcasing NS002 intranasal epinephrine for anaphylaxis treatment.

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.

Aardvark Therapeutics granted 152,338 stock options to six new hires with exercise prices of $13.48-$12.67, vesting over four years with a one-year cliff.